Understanding Tysabri Prescribing Information: What Every Patient Should Know
If you are suffering from Multiple Sclerosis (MS) or Crohn’s disease, you may be familiar with Tysabri – a medication that can help alleviate some of the symptoms. However, understanding the prescribing information for Tysabri is crucial for patients who are considering or taking this medication. In this article, we will delve into the details of Tysabri, explaining what it is, how it works, and what patients should know.
What is Tysabri?
Tysabri (natalizumab) is a medication used to treat MS and Crohn’s disease. MS is a condition that affects the nerves in the brain and spinal cord, while Crohn’s disease is a chronic inflammatory bowel disease. Tysabri works by preventing immune cells from crossing the blood-brain barrier and attacking the myelin sheath that surrounds nerve fibers.
How is Tysabri administered?
Tysabri is administered intravenously, meaning it is given through a needle placed into a vein. It is typically given once every 4 weeks. The dose and frequency of administration may differ for each patient and are typically determined by a doctor’s prescription.
Who should not take Tysabri?
Tysabri is not recommended for patients who have a history of Progressive Multifocal Leukoencephalopathy (PML). PML is a rare and serious brain infection that has been associated with Tysabri use. Patients who test positive for John Cunningham virus (JCV), a virus that can increase the risk of PML, should also not take this medication.
What are the potential side effects of Tysabri?
Although Tysabri is generally considered safe, there are potential side effects that patients should be aware of. The most common side effects include tiredness, headache, joint pain, and nausea. More severe side effects, such as PML, can occur but are rare. It is important to discuss any concerns with your doctor.
What are the precautions when taking Tysabri?
Patients taking Tysabri should be monitored closely for side effects. If any symptoms of PML are noted, such as confusion or difficulty speaking, patients should seek medical attention immediately. Other precautions include ensuring that blood tests are up-to-date and avoiding other medications that can increase the risk of PML. Patients should also inform their doctor if they are pregnant or planning on becoming pregnant, as the effects of Tysabri on developing fetuses are not yet fully understood.
In conclusion, understanding Tysabri prescribing information is essential for patients who are considering or taking this medication. Tysabri is a medication used to treat MS and Crohn’s disease that works by preventing immune cells from crossing the blood-brain barrier and attacking the myelin sheath. It is typically given once every 4 weeks intravenously. Patients who have a history of PML or test positive for JCV should not take Tysabri. While the medication is generally safe, patients should be aware of potential side effects and closely monitored by their doctor. With appropriate precautions and monitoring, Tysabri can help alleviate symptoms and improve quality of life for MS and Crohn’s disease patients.
